Page last updated: 2024-11-12

dc 88-a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

duocarmycin A: from a Streptomycete [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Dumagenus[no description available]PolygonaceaeThe only family of the buckwheat order (Polygonales) of dicotyledonous flowering plants. It has 40 genera of herbs, shrubs, and trees.[MeSH]

Cross-References

ID SourceID
PubMed CID11762918
CHEMBL ID161989
SCHEMBL ID19493154
MeSH IDM0162602

Synonyms (21)

Synonym
deuocarmycin a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r-(6alpha,7br*,8aalpha))-
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,3,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r,7br,8as)-
dc88-a
duocarmycin a
CHEMBL161989
118292-34-5
pjv9990868 ,
unii-pjv9990868
dc-88a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r-(6.alpha.,7br*,8a.alpha.))-
(+)-duocarmycin a
cyclopropa(c)pyrrolo(3,2-e)indole-6-carboxylic acid, 1,2,4,5,6,7,8,8a-octahydro-6-methyl-4,7-dioxo-2-((5,6,7-trimethoxy-1h-indol-2-yl)carbonyl)-, methyl ester, (6r,7br,8as)-
AKOS027256705
duma
SCHEMBL19493154
DTXSID40922656
HY-12455
CS-0011399
Q27286591
methyl (1r,4r,12s)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In vivo evaluation of the prodrug 6 showed that it exhibits extraordinary efficacy (T/C > 1500, L1210; 6/10 one year survivors), substantially exceeding that of the free drug, that its therapeutic window of activity is much larger, permitting a dosing ≥ 40-fold higher than the free drug, and yet that it displays a potency in vivo that approaches the free drug (within 3-fold)."( Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.
Boger, DL; Brown, D; Duncan, KK; Parelkar, NK; Vielhauer, GA; Wolfe, AL, 2013
)
0.39
" SYD983 could be dosed up to 30 mg/kg in cynomolgus monkeys with high exposure, excellent stability in blood, and without severe toxic effects."( Preclinical profile of the HER2-targeting ADC SYD983/SYD985: introduction of a new duocarmycin-based linker-drug platform.
Beusker, P; Coumans, R; de Groot, V; de Roo, G; Dokter, W; Egging, D; Elgersma, R; Eppink, M; Groothuis, P; Huijbregts, T; Jacobs, D; Joosten, J; Loosveld, E; Mattaar, E; Menge, W; Spijker, H; Timmers, M; Ubink, R; van Achterberg, T; van den Dobbelsteen, D; van der Lee, M; van der Vleuten, M; Verheijden, G, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (3.08)18.7374
1990's19 (29.23)18.2507
2000's20 (30.77)29.6817
2010's24 (36.92)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.19 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index5.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (7.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other64 (92.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]